Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404595 · ClinicalTrials.gov registry record · Phase 1
Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
A Phase 1 study of Pancreatic Cancer and Gastric Cancer, sponsored by CARsgen Therapeutics Co..
- Active
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 16
- Study locations
NCT04404595: Active Phase 1 study of Pancreatic Cancer and Gastric Cancer, sponsored by CARsgen Therapeutics Co..
NCT04404595 is a Phase 1 study of Pancreatic Cancer and Gastric Cancer that is active but no longer recruiting, run by CARsgen Therapeutics Co.. The registered enrollment target is 110 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (72% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04404595, a Phase 1 study of Pancreatic Cancer and Gastric Cancer, is active but no longer recruiting, sponsored by CARsgen Therapeutics Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 16
- Study locations
Study Summary
A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers
Primary Outcome
Incidence of adverse events (AEs), AEs of special interest (cytokine release syndrome \[CRS\], neurotoxicity, secondary malignancy), serious adverse events (SAEs).
Conditions Studied
Interventions
- BIOLOGICAL CT041
Study Locations (16)
California
- City of Hope - Duarte
- University of Southern California - Los Angeles
- UCSD - San Diego
- UCSF - San Francisco
New York
- Northwell Cancer Institute - New Hyde Park
- The Mount Sinai Hospital - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- TX Oncology-Baylor Charles Sammons Cancer Center - Dallas
- MD Anderson Cancer Center - Houston
Florida
- Moffitt Cancer Center - Tampa
Kansas
- University of Kansas Cancer Center - Kansas City
Michigan
- Karmanos Cancer Center - Detroit
Minnesota
- Mayo Cancer Hospital - Rochester
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2035-09-01 |
| Phase | Phase 1 |
What the registry record for NCT04404595 still lists
NCT04404595 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which CT041 is the first listed.
NCT04404595 lists 16 locations in 10 states (California, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT04404595 about?
NCT04404595 is a clinical study titled "Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers". A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers
What is the current status of trial NCT04404595?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2020-10-23. Estimated completion is 2035-09-01.
What conditions does trial NCT04404595 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Gastric Cancer.
What interventions are being tested in trial NCT04404595?
The interventions under investigation include: CT041 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04404595?
This trial is sponsored by CARsgen Therapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04404595 being conducted?
This trial has 16 study locations across California, Florida, Kansas, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04404595's enrollment target sits among peer trials
110 98th of 278 higher than 179 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03245411 · 110 participants · NA
Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI